Drug Profile


Alternative Names: CD24-Fc; CD24-Fc-IgG; CD24Fc-fusion protein; HAS-CD24; Recombinant CD24 IgG1 Fc fusion protein; Recombinant human CD24FcIg

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoImmune
  • Developer National Institute of Neurological Disorders and Stroke; Ohio State University; OncoImmune; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease
  • Phase I Autoimmune disorders

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Graft-versus-host disease (Prevention) in USA (IV) (NCT02663622)
  • 21 Jan 2016 University of Michigan Cancer Center and Ohio State University plans a phase II trial for Graft-versus-host disease (Prevention) in USA (NCT02663622)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top